{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:38:36Z","timestamp":1790793516229,"version":"4.1.0"},"reference-count":342,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP11105671"],"award-info":[{"award-number":["APP11105671"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["15\/ECF\/1-08"],"award-info":[{"award-number":["15\/ECF\/1-08"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Australia and Cure Cancer Australia","award":["1144868"],"award-info":[{"award-number":["1144868"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13046-019-1094-2","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T13:32:30Z","timestamp":1554989550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":205,"title":["Clinical development of targeted and immune based anti-cancer therapies"],"prefix":"10.1186","volume":"38","author":[{"given":"N. A.","family":"Seebacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. E.","family":"Stacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2599-3582","authenticated-orcid":false,"given":"A. M.","family":"Merlot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"issue":"6","key":"1094_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"1094_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.7150\/ijms.3635","volume":"9","author":"R Baskar","year":"2012","unstructured":"Baskar R, Lee KA, Yeo R, Yeoh K-W. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193\u20139.","journal-title":"Int J Med Sci."},{"key":"1094_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fphar.2013.00057","volume":"4","author":"MO Palumbo","year":"2013","unstructured":"Palumbo MO, Kavan P, Miller WH, Panasci L, Assouline S, Johnson N, et al. Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol. 2013;4:57.","journal-title":"Front Pharmacol."},{"issue":"6","key":"1094_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00066-002-0950-7","volume":"178","author":"A Schuck","year":"2002","unstructured":"Schuck A, Konemann S, Heinen K, Rube CE, Hesselmann S, Reinartz G, et al. Microscopic residual disease is a risk factor in the primary treatment of breast cancer. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft. 2002;178(6):307\u201313.","journal-title":"Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft."},{"key":"1094_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jpra.2017.04.001","volume":"13","author":"LK Jacobson","year":"2017","unstructured":"Jacobson LK, Johnson MB, Dedhia RD, Niknam-Bienia S, Wong AK. Impaired wound healing after radiation therapy: a systematic review of pathogenesis and treatment. JPRAS Open. 2017;13:92\u2013105.","journal-title":"JPRAS Open."},{"issue":"7","key":"1094_CR6","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S1470-2045(09)70082-8","volume":"10","author":"SC Formenti","year":"2009","unstructured":"Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10(7):718\u201326.","journal-title":"Lancet Oncol."},{"issue":"4 Suppl 1","key":"1094_CR7","first-page":"S2","volume":"2","author":"V Malhotra","year":"2003","unstructured":"Malhotra V, Perry MC. Classical chemotherapy: mechanisms, toxicities and the therapeutic window. Cancer Biol Ther. 2003;2(4 Suppl 1):S2\u20134.","journal-title":"Cancer Biol Ther."},{"issue":"2","key":"1094_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.molonc.2012.02.004","volume":"6","author":"S Hoelder","year":"2012","unstructured":"Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol. 2012;6(2):155\u201376.","journal-title":"Mol Oncol."},{"issue":"8","key":"1094_CR9","doi-asserted-by":"publisher","first-page":"13768","DOI":"10.3390\/ijms150813768","volume":"15","author":"M Hojjat-Farsangi","year":"2014","unstructured":"Hojjat-Farsangi M. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted Cancer therapies. Int J Mol Sci. 2014;15(8):13768\u2013801.","journal-title":"Int J Mol Sci."},{"issue":"2","key":"1094_CR10","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ceb.2009.01.014","volume":"21","author":"MJ Eck","year":"2009","unstructured":"Eck MJ, Manley PW. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Curr Opin Cell Biol. 2009;21(2):288\u201395.","journal-title":"Curr Opin Cell Biol."},{"key":"1094_CR11","first-page":"357027","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in Cancer. Chemother Res Pract. 2014;2014:357027.","journal-title":"Chemother Res Pract."},{"issue":"3","key":"1094_CR12","first-page":"39","volume":"1","author":"V Lavanya","year":"2014","unstructured":"Lavanya V, Mohamed Adil AA, Ahmed N, Rishi AK, Jamal S. Small molecule inhibitors as emerging cancer therapeutics. Integr Cancer Sci Therap. 2014;1(3):39\u201346.","journal-title":"Integr Cancer Sci Therap."},{"issue":"5","key":"1094_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.coph.2005.04.017","volume":"5","author":"JM Lambert","year":"2005","unstructured":"Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. 2005;5(5):543\u20139.","journal-title":"Curr Opin Pharmacol."},{"issue":"5\u20136","key":"1094_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2119\/molmed.2009.00007","volume":"15","author":"AA Argyriou","year":"2009","unstructured":"Argyriou AA, Kalofonos HP. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Mol Med. 2009;15(5\u20136):183\u201391.","journal-title":"Mol Med."},{"issue":"3","key":"1094_CR15","first-page":"215","volume":"1","author":"SA Jacobs","year":"2007","unstructured":"Jacobs SA. (90)Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin\u2019s lymphoma: current status and future prospects. Biologics. 2007;1(3):215\u201327.","journal-title":"Biologics."},{"issue":"4","key":"1094_CR16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/mabs.20230","volume":"4","author":"NWCJ Donk van de","year":"2012","unstructured":"van de Donk NWCJ, Dhimolea E. Brentuximab vedotin. mAbs. 2012;4(4):458\u201365.","journal-title":"mAbs"},{"issue":"2","key":"1094_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/1078155214527144","volume":"21","author":"JM Baron","year":"2015","unstructured":"Baron JM, Boster BL, Barnett CM. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. J Oncol Pharm Pract. 2015;21(2):132\u201342.","journal-title":"J Oncol Pharm Pract."},{"key":"1094_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fonc.2014.00063","volume":"4","author":"LM Hoffman","year":"2014","unstructured":"Hoffman LM, Gore L. Blinatumomab, a bi-specific anti-CD19\/CD3 BiTE(\u00ae) antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol. 2014;4:63.","journal-title":"Front Oncol."},{"issue":"2","key":"1094_CR19","volume":"4","author":"X Chen","year":"2016","unstructured":"Chen X, Cai H. Monoclonal antibodies for Cancer therapy approved by FDA. MOJ Immunol. 2016;4(2):00120.","journal-title":"MOJ Immunol."},{"issue":"5","key":"1094_CR20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell."},{"issue":"1","key":"1094_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98\u2013106.","journal-title":"Am J Clin Oncol."},{"key":"1094_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/ITT.S55415","volume":"4","author":"TL Whiteside","year":"2015","unstructured":"Whiteside TL. The role of regulatory T cells in cancer immunology. Immunotargets Ther. 2015;4:159\u201371.","journal-title":"Immunotargets Ther."},{"issue":"2","key":"1094_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","volume":"103","author":"J Schlessinger","year":"2000","unstructured":"Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103(2):211\u201325.","journal-title":"Cell."},{"issue":"5686","key":"1094_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/276409a0","volume":"276","author":"G Carpenter","year":"1978","unstructured":"Carpenter G, King L Jr, Cohen S. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature. 1978;276(5686):409\u201310.","journal-title":"Nature."},{"issue":"2","key":"1094_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/j.1460-2075.1989.tb03393.x","volume":"8","author":"I Lax","year":"1989","unstructured":"Lax I, Bellot F, Howk R, Ullrich A, Givol D, Schlessinger J. Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken\/human receptor molecules. EMBO J. 1989;8(2):421\u20137.","journal-title":"EMBO J."},{"issue":"2","key":"1094_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/emboj\/16.2.281","volume":"16","author":"MA Lemmon","year":"1997","unstructured":"Lemmon MA, Bu Z, Ladbury JE, Zhou M, Pinchasi D, Lax I, et al. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J. 1997;16(2):281\u201394.","journal-title":"EMBO J."},{"issue":"6","key":"1094_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S0092-8674(02)00940-6","volume":"110","author":"TP Garrett","year":"2002","unstructured":"Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 2002;110(6):763\u201373.","journal-title":"Cell."},{"key":"1094_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0065-2423(10)51004-7","volume":"51","author":"B Markman","year":"2010","unstructured":"Markman B, Javier Ramos F, Capdevila J, Tabernero J. EGFR and KRAS in colorectal cancer. Adv Clin Chem. 2010;51:71\u2013119.","journal-title":"Adv Clin Chem."},{"issue":"12","key":"1094_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030485","volume":"3","author":"JC Lee","year":"2006","unstructured":"Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006;3(12):e485.","journal-title":"PLoS Med."},{"issue":"6835","key":"1094_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/35077225","volume":"411","author":"P Blume-Jensen","year":"2001","unstructured":"Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355\u201365.","journal-title":"Nature."},{"issue":"1a","key":"1094_CR31","first-page":"1","volume":"22","author":"VW Lui","year":"2002","unstructured":"Lui VW, Grandis JR. EGFR-mediated cell cycle regulation. Anticancer Res. 2002;22(1a):1\u201311.","journal-title":"Anticancer Res."},{"issue":"87","key":"1094_CR32","doi-asserted-by":"publisher","first-page":"re6","DOI":"10.1126\/scisignal.287re6","volume":"2","author":"PH Huang","year":"2009","unstructured":"Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal. 2009;2(87):re6.","journal-title":"Sci Signal"},{"issue":"9","key":"1094_CR33","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892\u2013911.","journal-title":"Am J Cancer Res."},{"issue":"5","key":"1094_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jnci\/dji055","volume":"97","author":"H Shigematsu","year":"2005","unstructured":"Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339\u201346.","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"1094_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/sj.bjc.6602707","volume":"93","author":"M Sonobe","year":"2005","unstructured":"Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer. 2005;93(3):355\u201363.","journal-title":"Br J Cancer."},{"issue":"6","key":"1094_CR36","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.cell.2006.05.013","volume":"125","author":"X Zhang","year":"2006","unstructured":"Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 2006;125(6):1137\u201349.","journal-title":"Cell."},{"issue":"12","key":"1094_CR37","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0959-8049(96)00243-2","volume":"32a","author":"S Fujino","year":"1996","unstructured":"Fujino S, Enokibori T, Tezuka N, Asada Y, Inoue S, Kato H, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer. 1996;32a(12):2070\u20134.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1094_CR38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/annonc\/mdm492","volume":"19","author":"F Cappuzzo","year":"2008","unstructured":"Cappuzzo F, Finocchiaro G, Rossi E, Janne PA, Carnaghi C, Calandri C, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol. 2008;19(4):717\u201323.","journal-title":"Ann Oncol."},{"issue":"1","key":"1094_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14728222.2011.648617","volume":"16","author":"P Seshacharyulu","year":"2012","unstructured":"Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti A, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):15\u201331.","journal-title":"Expert Opin Ther Targets."},{"issue":"11","key":"1094_CR40","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1056\/NEJMra0707704","volume":"358","author":"F Ciardiello","year":"2008","unstructured":"Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160\u201374.","journal-title":"N Engl J Med."},{"issue":"1","key":"1094_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/erc.0.0100001","volume":"10","author":"N Normanno","year":"2003","unstructured":"Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 2003;10(1):1\u201321.","journal-title":"Endocr Relat Cancer."},{"issue":"6","key":"1094_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2165\/11587020-000000000-00000","volume":"50","author":"M Scheffler","year":"2011","unstructured":"Scheffler M, Di Gion P, Doroshyenko O, Wolf J, Fuhr U. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet. 2011;50(6):371\u2013403.","journal-title":"Clin Pharmacokinet."},{"issue":"36","key":"1094_CR43","doi-asserted-by":"publisher","first-page":"13306","DOI":"10.1073\/pnas.0405220101","volume":"101","author":"W Pao","year":"2004","unstructured":"Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101(36):13306\u201311.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"21","key":"1094_CR44","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129\u201339.","journal-title":"N Engl J Med."},{"issue":"5676","key":"1094_CR45","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497\u2013500.","journal-title":"Science."},{"issue":"4","key":"1094_CR46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","volume":"8","author":"MH Cohen","year":"2003","unstructured":"Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003;8(4):303\u20136.","journal-title":"Oncologist."},{"issue":"6","key":"1094_CR47","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-15-2266","volume":"22","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D, Blumenthal GM, Yuan W, He K, Keegan P, Pazdur R. FDA approval of Gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung Cancer. Clin Cancer Res. 2016;22(6):1307\u201312.","journal-title":"Clin Cancer Res."},{"issue":"10","key":"1094_CR48","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357.","journal-title":"N Engl J Med."},{"issue":"4","key":"1094_CR49","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/JTO.0000000000000445","volume":"10","author":"H Zhao","year":"2015","unstructured":"Zhao H, Fan Y, Ma S, Song X, Han B, Cheng Y, et al. Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). J Thorac Oncol. 2015;10(4):655\u201364.","journal-title":"J Thorac Oncol."},{"issue":"9496","key":"1094_CR50","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","volume":"366","author":"N Thatcher","year":"2005","unstructured":"Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527\u201337.","journal-title":"Lancet."},{"issue":"5","key":"1094_CR51","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/138920009788897975","volume":"10","author":"JT Hartmann","year":"2009","unstructured":"Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10(5):470\u201381.","journal-title":"Curr Drug Metab."},{"issue":"9","key":"1094_CR52","first-page":"2531","volume":"5","author":"M Segovia-Mendoza","year":"2015","unstructured":"Segovia-Mendoza M, Gonz\u00e1lez-Gonz\u00e1lez ME, Barrera D, D\u00edaz L, Garc\u00eda-Becerra R. Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. Am J Cancer Res. 2015;5(9):2531\u201361.","journal-title":"Am J Cancer Res."},{"issue":"1","key":"1094_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.critrevonc.2005.08.008","volume":"58","author":"F Cappuzzo","year":"2006","unstructured":"Cappuzzo F, Finocchiaro G, Metro G, Bartolini S, Magrini E, Cancellieri A, et al. Clinical experience with gefitinib: an update. Crit Rev Oncol Hematol. 2006;58(1):31\u201345.","journal-title":"Crit Rev Oncol Hematol."},{"issue":"6","key":"1094_CR54","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3816\/CLC.2003.n.016","volume":"4","author":"RS Herbst","year":"2003","unstructured":"Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer. 2003;4(6):366\u20139.","journal-title":"Clin Lung Cancer."},{"issue":"Suppl 1","key":"1094_CR55","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/S0169-5002(03)00136-3","volume":"41","author":"DH Johnson","year":"2003","unstructured":"Johnson DH. Gefitinib (Iressa) trials in non-small cell lung cancer. Lung Cancer. 2003;41(Suppl 1):S23\u20138.","journal-title":"Lung Cancer."},{"issue":"48","key":"1094_CR56","doi-asserted-by":"publisher","first-page":"46265","DOI":"10.1074\/jbc.M207135200","volume":"277","author":"J Stamos","year":"2002","unstructured":"Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem. 2002;277(48):46265\u201372.","journal-title":"J Biol Chem."},{"issue":"7","key":"1094_CR57","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","volume":"10","author":"MH Cohen","year":"2005","unstructured":"Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005;10(7):461\u20136.","journal-title":"Oncologist."},{"issue":"2","key":"1094_CR58","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123\u201332.","journal-title":"N Engl J Med."},{"issue":"15S","key":"1094_CR59","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/jco.2009.27.15_suppl.8001","volume":"27","author":"F Cappuzzo","year":"2009","unstructured":"Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol. 2009;27(15S):8001.","journal-title":"J Clin Oncol."},{"issue":"3","key":"1094_CR60","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jaad.2013.02.025","volume":"69","author":"Y Kiyohara","year":"2013","unstructured":"Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol. 2013;69(3):463\u201372.","journal-title":"J Am Acad Dermatol."},{"issue":"7","key":"1094_CR61","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1358\/dot.2006.42.7.985637","volume":"42","author":"SR Johnston","year":"2006","unstructured":"Johnston SR, Leary A. Lapatinib: a novel EGFR\/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc). 2006;42(7):441\u201353.","journal-title":"Drugs Today (Barc)."},{"issue":"9","key":"1094_CR62","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1634\/theoncologist.2009-0181","volume":"15","author":"D Cameron","year":"2010","unstructured":"Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus Capecitabine in women with HER-2\u2013positive advanced breast Cancer: final survival analysis of a Phase III randomized trial. Oncologist. 2010;15(9):924\u201334.","journal-title":"Oncologist."},{"issue":"17","key":"1094_CR63","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1200\/JCO.2011.40.1315","volume":"30","author":"PA Janne","year":"2012","unstructured":"Janne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol. 2012;30(17):2063\u20139.","journal-title":"J Clin Oncol."},{"issue":"25","key":"1094_CR64","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380\u20138.","journal-title":"N Engl J Med."},{"issue":"3","key":"1094_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020073","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.","journal-title":"PLoS Med."},{"issue":"20","key":"1094_CR66","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1056\/NEJM200505193522019","volume":"352","author":"S Toyooka","year":"2005","unstructured":"Toyooka S, Kiura K, Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. N Engl J Med. 2005;352(20):2136 author reply.","journal-title":"N Engl J Med"},{"issue":"34","key":"1094_CR67","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1038\/onc.2008.109","volume":"27","author":"D Li","year":"2008","unstructured":"Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702\u201311.","journal-title":"Oncogene."},{"issue":"1","key":"1094_CR68","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1021\/jm020241c","volume":"46","author":"A Wissner","year":"2003","unstructured":"Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, et al. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J Med Chem. 2003;46(1):49\u201363.","journal-title":"J Med Chem."},{"issue":"3","key":"1094_CR69","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1021\/jm000372i","volume":"44","author":"JB Smaill","year":"2001","unstructured":"Smaill JB, Showalter HD, Zhou H, Bridges AJ, McNamara DJ, Fry DW, et al. Tyrosine kinase inhibitors. 18. 6-substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. J Med Chem. 2001;44(3):429\u201340.","journal-title":"J Med Chem."},{"issue":"4","key":"1094_CR70","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1021\/jm040159c","volume":"48","author":"HR Tsou","year":"2005","unstructured":"Tsou HR, Overbeek-Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem. 2005;48(4):1107\u201331.","journal-title":"J Med Chem."},{"issue":"24","key":"1094_CR71","doi-asserted-by":"publisher","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","volume":"67","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007;67(24):11924\u201332.","journal-title":"Cancer Res."},{"issue":"1","key":"1094_CR72","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0014-4827(02)00095-2","volume":"284","author":"DW Fry","year":"2003","unstructured":"Fry DW. Mechanism of action of erbB tyrosine kinase inhibitors. Exp Cell Res. 2003;284(1):131\u20139.","journal-title":"Exp Cell Res."},{"issue":"20","key":"1094_CR73","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.2174\/092986711796391705","volume":"18","author":"L Garuti","year":"2011","unstructured":"Garuti L, Roberti M, Bottegoni G. Irreversible protein kinase inhibitors. Curr Med Chem. 2011;18(20):2981\u201394.","journal-title":"Curr Med Chem."},{"issue":"11","key":"1094_CR74","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1016\/j.bmc.2007.03.055","volume":"15","author":"A Wissner","year":"2007","unstructured":"Wissner A, Fraser HL, Ingalls CL, Dushin RG, Floyd MB, Cheung K, et al. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. Bioorg Med Chem. 2007;15(11):3635\u201348.","journal-title":"Bioorg Med Chem."},{"issue":"4","key":"1094_CR75","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1634\/theoncologist.2008-0261","volume":"14","author":"A Morabito","year":"2009","unstructured":"Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist. 2009;14(4):378\u201390.","journal-title":"Oncologist."},{"key":"1094_CR76","first-page":"147","volume":"7","author":"K Feldinger","year":"2015","unstructured":"Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer. 2015;7:147\u201362.","journal-title":"Breast Cancer."},{"issue":"7","key":"1094_CR77","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1158\/1535-7163.MCT-07-2232","volume":"7","author":"AJ Gonzales","year":"2008","unstructured":"Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, Delaney AM, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2008;7(7):1880\u20139.","journal-title":"Mol Cancer Ther."},{"issue":"11","key":"1094_CR78","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","volume":"64","author":"SK Rabindran","year":"2004","unstructured":"Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64(11):3958\u201365.","journal-title":"Cancer Res."},{"issue":"16","key":"1094_CR79","first-page":"4645","volume":"62","author":"SR Wedge","year":"2002","unstructured":"Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62(16):4645\u201355.","journal-title":"Cancer Res."},{"issue":"9","key":"1094_CR80","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/79534","volume":"6","author":"CJ Torrance","year":"2000","unstructured":"Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 2000;6(9):1024\u20138.","journal-title":"Nat Med."},{"issue":"7","key":"1094_CR81","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1021\/jm990482t","volume":"43","author":"JB Smaill","year":"2000","unstructured":"Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem. 2000;43(7):1380\u201397.","journal-title":"J Med Chem."},{"issue":"2","key":"1094_CR82","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1124\/jpet.112.197756","volume":"343","author":"F Solca","year":"2012","unstructured":"Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342\u201350.","journal-title":"J Pharmacol Exp Ther."},{"issue":"4","key":"1094_CR83","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1021\/acsomega.7b00157","volume":"2","author":"S Smith","year":"2017","unstructured":"Smith S, Keul M, Engel J, Basu D, Eppmann S, Rauh D. Characterization of covalent-reversible EGFR inhibitors. ACS Omega. 2017;2(4):1563\u201375.","journal-title":"ACS Omega."},{"key":"1094_CR84","first-page":"135","volume":"6","author":"V Nelson","year":"2013","unstructured":"Nelson V, Ziehr J, Agulnik M, Johnson M. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. OncoTargets Therapy. 2013;6:135\u201343.","journal-title":"OncoTargets Therapy."},{"issue":"6","key":"1094_CR85","first-page":"456","volume":"37","author":"G Giaccone","year":"2011","unstructured":"Giaccone G, Wang Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev. 2011;37(6):456\u201364.","journal-title":"Cancer Treat Rev."},{"issue":"5","key":"1094_CR86","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1158\/1535-7163.MCT-12-0885","volume":"12","author":"T Ninomiya","year":"2013","unstructured":"Ninomiya T, Takigawa N, Ichihara E, Ochi N, Murakami T, Honda Y, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther. 2013;12(5):589\u201397.","journal-title":"Mol Cancer Ther."},{"issue":"27","key":"1094_CR87","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327\u201334.","journal-title":"J Clin Oncol."},{"issue":"15_suppl","key":"1094_CR88","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.1200\/jco.2013.31.15_suppl.8061","volume":"31","author":"SL Geater","year":"2013","unstructured":"Geater SL, Zhou C, Hu C-P, Feng JF, Lu S, Huang Y, et al. LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations. J Clin Oncol. 2013;31(15_suppl):8061.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1094_CR89","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"YL Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213\u201322.","journal-title":"Lancet Oncol."},{"issue":"2","key":"1094_CR90","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","volume":"16","author":"JC Yang","year":"2015","unstructured":"Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-lung 3 and LUX-lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141\u201351.","journal-title":"Lancet Oncol."},{"issue":"3","key":"1094_CR91","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s10549-012-2003-y","volume":"133","author":"NU Lin","year":"2012","unstructured":"Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012;133(3):1057\u201365.","journal-title":"Breast Cancer Res Treat."},{"issue":"9","key":"1094_CR92","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1158\/1535-7163.MCT-11-0730","volume":"11","author":"O Kalous","year":"2012","unstructured":"Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, et al. Dacomitinib (PF-00299804), an irreversible pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther. 2012;11(9):1978\u201387.","journal-title":"Mol Cancer Ther."},{"issue":"11","key":"1094_CR93","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454\u201366.","journal-title":"Lancet Oncol."},{"issue":"14","key":"1094_CR94","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-12-0411","volume":"18","author":"K Thornton","year":"2012","unstructured":"Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2012;18(14):3722\u201330.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"1094_CR95","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","volume":"1","author":"ES Kim","year":"2011","unstructured":"Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44\u201353.","journal-title":"Cancer Discov."},{"issue":"8","key":"1094_CR96","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","volume":"29","author":"RB Natale","year":"2011","unstructured":"Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(8):1059\u201366.","journal-title":"J Clin Oncol."},{"issue":"2","key":"1094_CR97","doi-asserted-by":"publisher","first-page":"161","DOI":"10.6004\/jnccn.2013.0024","volume":"11","author":"HA Yu","year":"2013","unstructured":"Yu HA, Riely GJ. Second generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw. 2013;11(2):161\u20139.","journal-title":"J Natl Compr Canc Netw."},{"issue":"3","key":"1094_CR98","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","volume":"17","author":"A Chan","year":"2016","unstructured":"Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367\u201377.","journal-title":"Lancet Oncol."},{"issue":"2","key":"1094_CR99","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/JCO.2012.47.2787","volume":"32","author":"L Gandhi","year":"2014","unstructured":"Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, et al. Phase I study of Neratinib in combination with Temsirolimus in patients with human epidermal growth factor receptor 2\u2013dependent and other solid tumors. J Clin Oncol. 2014;32(2):68\u201375.","journal-title":"J Clin Oncol."},{"issue":"6","key":"1094_CR100","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00210-014-0967-3","volume":"387","author":"H Modjtahedi","year":"2014","unstructured":"Modjtahedi H, Cho BC, Michel MC, Solca F. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedeberg\u2019s Arch Pharmacol. 2014;387(6):505\u201321.","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol."},{"key":"1094_CR101","volume-title":"2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer","author":"S Butterworth","year":"2013","unstructured":"Butterworth S, Finlay MRV, Ward RA, Kadambar VK, Chandrashekar RC, Murugan A, et al. 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer. Google Patents; 2013."},{"issue":"8","key":"1094_CR102","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786\u201392.","journal-title":"N Engl J Med."},{"key":"1094_CR103","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.canlet.2018.02.004","volume":"420","author":"ZH Tang","year":"2018","unstructured":"Tang ZH, Lu JJ. Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Lett. 2018;420:242\u20136.","journal-title":"Cancer Lett."},{"issue":"12","key":"1094_CR104","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-13-0314","volume":"3","author":"AO Walter","year":"2013","unstructured":"Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013;3(12):1404\u201315.","journal-title":"Cancer Discov."},{"issue":"18","key":"1094_CR105","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1056\/NEJMoa1413654","volume":"372","author":"LV Sequist","year":"2015","unstructured":"Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372(18):1700\u20139.","journal-title":"N Engl J Med."},{"issue":"11","key":"1094_CR106","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s40265-016-0606-z","volume":"76","author":"ES Kim","year":"2016","unstructured":"Kim ES. Olmutinib: first global approval. Drugs. 2016;76(11):1153\u20137.","journal-title":"Drugs."},{"issue":"3","key":"1094_CR107","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s10120-011-0102-9","volume":"15","author":"B Hotz","year":"2012","unstructured":"Hotz B, Keilholz U, Fusi A, Buhr HJ, Hotz HG. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. Gastric Cancer. 2012;15(3):252\u201364.","journal-title":"Gastric Cancer."},{"issue":"11","key":"1094_CR108","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa074943","volume":"358","author":"CH Chung","year":"2008","unstructured":"Chung CH, Mirakhur B, Chan E, Le Q-T, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose. N Engl J Med. 2008;358(11):1109\u201317.","journal-title":"N Engl J Med."},{"issue":"6","key":"1094_CR109","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1158\/1535-7163.MCT-08-0978","volume":"8","author":"DJ Freeman","year":"2009","unstructured":"Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther. 2009;8(6):1536\u201346.","journal-title":"Mol Cancer Ther."},{"issue":"16","key":"1094_CR110","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1158\/1078-0432.CCR-07-0065","volume":"13","author":"WA Messersmith","year":"2007","unstructured":"Messersmith WA, Hidalgo M. Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one? Clin Cancer Res. 2007;13(16):4664\u20136.","journal-title":"Clin Cancer Res."},{"issue":"7 Supplement","key":"1094_CR111","first-page":"163","volume":"64","author":"M Liu","year":"2004","unstructured":"Liu M, Zhang H, Jimenez X, Ludwig D, Witte L, Bohlen P, et al. Identification and characterization of a fully human antibody directed against epidermal growth factor receptor for cancer therapy. Cancer Res. 2004;64(7 Supplement):163.","journal-title":"Cancer Res."},{"key":"1094_CR112","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.2147\/OTT.S114039","volume":"9","author":"C Genova","year":"2016","unstructured":"Genova C, Hirsch FR. Clinical potential of necitumumab in non-small cell lung carcinoma. OncoTargets Ther. 2016;9:5427\u201337.","journal-title":"OncoTargets Ther."},{"issue":"1","key":"1094_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2009.03992.x","volume":"158","author":"E Martinelli","year":"2009","unstructured":"Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol. 2009;158(1):1\u20139.","journal-title":"Clin Exp Immunol."},{"issue":"5a","key":"1094_CR114","first-page":"3355","volume":"27","author":"D Patel","year":"2007","unstructured":"Patel D, Lahiji A, Patel S, Franklin M, Jimenez X, Hicklin DJ, et al. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res. 2007;27(5a):3355\u201366.","journal-title":"Anticancer Res."},{"issue":"4","key":"1094_CR115","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1634\/theoncologist.2012-0458","volume":"18","author":"MH Cohen","year":"2013","unstructured":"Cohen MH, Chen H, Shord S, Fuchs C, He K, Zhao H, et al. Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Oncologist. 2013;18(4):460\u20136.","journal-title":"Oncologist."},{"issue":"17","key":"1094_CR116","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757\u201365.","journal-title":"N Engl J Med."},{"issue":"35","key":"1094_CR117","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","volume":"26","author":"F Nicolantonio Di","year":"2008","unstructured":"Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705\u201312.","journal-title":"J Clin Oncol."},{"issue":"10","key":"1094_CR118","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for Panitumumab efficacy in patients with metastatic colorectal Cancer. J Clin Oncol. 2008;26(10):1626\u201334.","journal-title":"J Clin Oncol."},{"key":"1094_CR119","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jbior.2015.06.003","volume":"59","author":"TL Fitzgerald","year":"2015","unstructured":"Fitzgerald TL, Lertpiriyapong K, Cocco L, Martelli AM, Libra M, Candido S, et al. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. Adv Biol Regul. 2015;59:65\u201381.","journal-title":"Adv Biol Regul."},{"issue":"8","key":"1094_CR120","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","volume":"66","author":"A Lievre","year":"2006","unstructured":"Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992\u20135.","journal-title":"Cancer Res."},{"issue":"1","key":"1094_CR121","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/CAD.0b013e32800feecb","volume":"18","author":"M Cohenuram","year":"2007","unstructured":"Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anti-Cancer Drugs. 2007;18(1):7\u201315.","journal-title":"Anti-Cancer Drugs."},{"issue":"1","key":"1094_CR122","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/1078155216682365","volume":"24","author":"JK Brinkmeyer","year":"2018","unstructured":"Brinkmeyer JK, Moore DC. Necitumumab for the treatment of squamous cell non-small cell lung cancer. J Oncol Pharm Pract. 2018;24(1):37\u201341.","journal-title":"J Oncol Pharm Pract."},{"issue":"3","key":"1094_CR123","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S1470-2045(15)70046-X","volume":"16","author":"L Paz-Ares","year":"2015","unstructured":"Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015;16(3):328\u201337.","journal-title":"Lancet Oncol."},{"issue":"8","key":"1094_CR124","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.2174\/138945010791591395","volume":"11","author":"G Niu","year":"2010","unstructured":"Niu G, Chen X. Vascular endothelial growth factor as an anti-angiogenic target for Cancer therapy. Curr Drug Targets. 2010;11(8):1000\u201317.","journal-title":"Curr Drug Targets."},{"issue":"2","key":"1094_CR125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009072","volume":"5","author":"Y Yu","year":"2010","unstructured":"Yu Y, Lee P, Ke Y, Zhang Y, Yu Q, Lee J, et al. A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS One. 2010;5(2):e9072.","journal-title":"PLoS One."},{"issue":"2","key":"1094_CR126","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","volume":"333","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328\u201335.","journal-title":"Biochem Biophys Res Commun."},{"issue":"20","key":"1094_CR127","first-page":"4593","volume":"57","author":"LG Presta","year":"1997","unstructured":"Presta LG, Chen H, Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593.","journal-title":"Cancer Res."},{"key":"1094_CR128","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc2403","volume":"8","author":"LM Ellis","year":"2008","unstructured":"Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579.","journal-title":"Nat Rev Cancer."},{"issue":"15","key":"1094_CR129","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1073\/pnas.0813061106","volume":"106","author":"F Zhang","year":"2009","unstructured":"Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW, et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci. 2009;106(15):6152.","journal-title":"Proc Natl Acad Sci."},{"key":"1094_CR130","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669.","journal-title":"Nat Med."},{"issue":"Suppl. 3","key":"1094_CR131","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000088478","volume":"69","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet P. VEGF as a Key Mediator of Angiogenesis in Cancer. Oncology. 2005;69(Suppl. 3):4\u201310.","journal-title":"Oncology."},{"issue":"1","key":"1094_CR132","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood-2013-02-485011","volume":"123","author":"EM Battinelli","year":"2014","unstructured":"Battinelli EM, Markens BA, Kulenthirarajan RA, Machlus KR, Flaumenhaft R, Italiano JE. Anticoagulation inhibits tumor cell\u2013mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood. 2014;123(1):101.","journal-title":"Blood."},{"issue":"20","key":"1094_CR133","first-page":"4575","volume":"55","author":"J Rak","year":"1995","unstructured":"Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, et al. Mutant <em>ras<\/em> oncogenes upregulate VEGF\/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995;55(20):4575\u201380.","journal-title":"Cancer Res."},{"key":"1094_CR134","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.2741\/2230","volume":"12","author":"J Hanson","year":"2007","unstructured":"Hanson J, Gorman J, Reese J, Fraizer G. Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. Front Biosci. 2007;12:2279\u201390.","journal-title":"Front Biosci."},{"issue":"7","key":"1094_CR135","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1093\/carcin\/bgq085","volume":"31","author":"T Tian","year":"2010","unstructured":"Tian T, Nan K-J, Wang S-H, Liang X, Lu C-X, Guo H, et al. PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells. Carcinogenesis. 2010;31(7):1211\u20139.","journal-title":"Carcinogenesis."},{"key":"1094_CR136","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1053\/j.seminoncol.2006.08.001","volume":"33","author":"H Hurwitz","year":"2006","unstructured":"Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal Cancer: safety profile and Management of Adverse Events. Semin Oncol. 2006;33:S26\u201334.","journal-title":"Semin Oncol."},{"issue":"7","key":"1094_CR137","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1634\/theoncologist.11-7-753","volume":"11","author":"A Morabito","year":"2006","unstructured":"Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist. 2006;11(7):753\u201364.","journal-title":"Oncologist."},{"key":"1094_CR138","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788.","journal-title":"Br J Cancer."},{"issue":"2","key":"1094_CR139","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125\u201334.","journal-title":"N Engl J Med."},{"issue":"4","key":"1094_CR140","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med."},{"issue":"9940","key":"1094_CR141","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319\u201328.","journal-title":"Lancet."},{"issue":"9","key":"1094_CR142","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1634\/theoncologist.2011-0439","volume":"17","author":"P Boudou-Rouquette","year":"2012","unstructured":"Boudou-Rouquette P, Ropert S, Mir O, Coriat R, Billemont B, Tod M, et al. Variability of Sorafenib toxicity and exposure over time: a pharmacokinetic\/Pharmacodynamic analysis. Oncologist. 2012;17(9):1204\u201312.","journal-title":"Oncologist."},{"issue":"2","key":"1094_CR143","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/02841860701765675","volume":"47","author":"D Chu","year":"2008","unstructured":"Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47(2):176\u201386.","journal-title":"Acta Oncol."},{"issue":"9","key":"1094_CR144","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","volume":"13","author":"ME Lacouture","year":"2008","unstructured":"Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13(9):1001\u201311.","journal-title":"Oncologist."},{"issue":"5","key":"1094_CR145","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000258880","volume":"77","author":"AD Lipworth","year":"2009","unstructured":"Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77(5):257\u201371.","journal-title":"Oncology."},{"issue":"6","key":"1094_CR146","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/FPC.0000000000000279","volume":"27","author":"L Gong","year":"2017","unstructured":"Gong L, Giacomini MM, Giacomini C, Maitland ML, Altman RB, Klein TE. PharmGKB summary: Sorafenib pathways. Pharmacogenet Genomics. 2017;27(6):240\u20136.","journal-title":"Pharmacogenet Genomics."},{"issue":"9668","key":"1094_CR147","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(09)60251-8","volume":"373","author":"LM Weiner","year":"2009","unstructured":"Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal Antibodies for Cancer Immunotherapy. Lancet. 2009;373(9668):1033\u201340.","journal-title":"Lancet."},{"issue":"5","key":"1094_CR148","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1073\/pnas.1424024112","volume":"112","author":"RS Heist","year":"2015","unstructured":"Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, et al. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci. 2015;112(5):1547.","journal-title":"Proc Natl Acad Sci."},{"key":"1094_CR149","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nm988","volume":"10","author":"CG Willett","year":"2004","unstructured":"Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145.","journal-title":"Nat Med."},{"key":"1094_CR150","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminoncol.2006.08.002","volume":"33","author":"LM Ellis","year":"2006","unstructured":"Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal Cancer. Semin Oncol. 2006;33:S1\u20137.","journal-title":"Semin Oncol."},{"issue":"5","key":"1094_CR151","first-page":"5291","volume":"8","author":"L-L Wang","year":"2015","unstructured":"Wang L-L, Hu R-C, Dai A-G, Tan S-X. Bevacizumab induces A549 cell apoptosis through the mechanism of endoplasmic reticulum stress in vitro. Int J Clin Exp Pathol. 2015;8(5):5291\u20139.","journal-title":"Int J Clin Exp Pathol."},{"issue":"3","key":"1094_CR152","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bcp.2007.09.029","volume":"75","author":"M Selvakumaran","year":"2008","unstructured":"Selvakumaran M, Yao KS, Feldman MD, O\u2019Dwyer PJ. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol. 2008;75(3):627\u201338.","journal-title":"Biochem Pharmacol."},{"issue":"12","key":"1094_CR153","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013\u20139.","journal-title":"J Clin Oncol."},{"issue":"11","key":"1094_CR154","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung Cancer. J Clin Oncol. 2004;22(11):2184\u201391.","journal-title":"J Clin Oncol."},{"issue":"3","key":"1094_CR155","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00280-014-2384-1","volume":"73","author":"JJ Wheler","year":"2014","unstructured":"Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, et al. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014;73(3):495\u2013501.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"5","key":"1094_CR156","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740\u20135.","journal-title":"J Clin Oncol."},{"issue":"9605","key":"1094_CR157","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103\u201311.","journal-title":"Lancet."},{"issue":"3","key":"1094_CR158","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ygyno.2015.06.041","volume":"139","author":"KC Fuh","year":"2015","unstructured":"Fuh KC, Secord AA, Bevis KS, Huh W, ElNaggar A, Blansit K, et al. Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. Gynecol Oncol. 2015;139(3):413\u20138.","journal-title":"Gynecol Oncol."},{"issue":"6","key":"1094_CR159","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1634\/theoncologist.12-6-713","volume":"12","author":"MH Cohen","year":"2007","unstructured":"Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced\/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12(6):713\u20138.","journal-title":"Oncologist."},{"issue":"16","key":"1094_CR160","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","volume":"23","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23(16):3697\u2013705.","journal-title":"J Clin Oncol."},{"issue":"9911","key":"1094_CR161","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31\u20139.","journal-title":"Lancet."},{"issue":"11","key":"1094_CR162","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh S-C, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u201335.","journal-title":"Lancet Oncol."},{"issue":"9944","key":"1094_CR163","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, Ciuleanu T-E, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665\u201373.","journal-title":"Lancet."},{"issue":"7","key":"1094_CR164","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1177\/1078155216655474","volume":"23","author":"A Vennepureddy","year":"2017","unstructured":"Vennepureddy A, Singh P, Rastogi R, Atallah JP, Terjanian T. Evolution of ramucirumab in the treatment of cancer - a review of literature. J Oncol Pharm Pract. 2017;23(7):525\u201339.","journal-title":"J Oncol Pharm Pract."},{"issue":"8","key":"1094_CR165","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1517\/14712598.2013.810717","volume":"13","author":"JM Clarke","year":"2013","unstructured":"Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther. 2013;13(8):1187\u201396.","journal-title":"Expert Opin Biol Ther."},{"issue":"28","key":"1094_CR166","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Cutsem Van","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausov\u00e1 J, Macarulla T, et al. Addition of Aflibercept to fluorouracil, Leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal Cancer previously treated with an Oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499\u2013506.","journal-title":"J Clin Oncol."},{"issue":"4","key":"1094_CR167","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3322\/caac.20075","volume":"60","author":"KM Cook","year":"2010","unstructured":"Cook KM, Figg WD. Angiogenesis inhibitors \u2013 current strategies and future prospects. CA Cancer J Clin. 2010;60(4):222\u201343.","journal-title":"CA Cancer J Clin."},{"issue":"6","key":"1094_CR168","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/1756283X13502637","volume":"6","author":"PA Tang","year":"2013","unstructured":"Tang PA, Moore MJ. Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Ther Adv Gastroenterol. 2013;6(6):459\u201373.","journal-title":"Ther Adv Gastroenterol."},{"issue":"Suppl 2","key":"1094_CR169","doi-asserted-by":"publisher","first-page":"ii46","DOI":"10.1093\/annonc\/mdw199.150","volume":"27","author":"F Bibeau","year":"2016","unstructured":"Bibeau F, Goldman-Levy G, Artru P, Desrame J, Lledo G, Mithieux F, et al. P-156Pathologic response of liver metastases from colorectal cancer after chemotherapy and aflibercept: initial report of 23 cases from 9 patients. Ann Oncol. 2016;27(Suppl 2):ii46\u2013ii.","journal-title":"Ann Oncol"},{"issue":"8","key":"1094_CR170","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","volume":"14","author":"IF Tannock","year":"2013","unstructured":"Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fl\u00e9chon A, Skoneczna I, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013;14(8):760\u20138.","journal-title":"Lancet Oncol."},{"issue":"5","key":"1094_CR171","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ctrv.2011.12.008","volume":"38","author":"A Gaya","year":"2012","unstructured":"Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev. 2012;38(5):484\u201393.","journal-title":"Cancer Treat Rev."},{"issue":"14","key":"1094_CR172","first-page":"6643","volume":"52","author":"JA Haller","year":"2011","unstructured":"Haller JA, Boyer DS, Heier JS, Brown DM, Clark L, RVEGF V. Trap-Eye In CRVO: Primary Endpoint Results Of The Phase 3 COPERNICUS Study. Invest Ophthalmol Vis Sci. 2011;52(14):6643.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"1094_CR173","first-page":"1817","volume":"7","author":"L Li","year":"2014","unstructured":"Li L, Ma BBY. Colorectal cancer in Chinese patients: current and emerging treatment options. OncoTargets Ther. 2014;7:1817\u201328.","journal-title":"OncoTargets Ther."},{"issue":"3_suppl","key":"1094_CR174","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1200\/jco.2014.32.3_suppl.545","volume":"32","author":"R Bordonaro","year":"2014","unstructured":"Bordonaro R, Sobrero AF, Frassineti L, Ciuffreda L, Aprile G, Thomas AL, et al. Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients \u226565. J Clin Oncol. 2014;32(3_suppl):545.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1094_CR175","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1470-2045(11)70338-2","volume":"13","author":"WH Gotlieb","year":"2012","unstructured":"Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012;13(2):154\u201362.","journal-title":"Lancet Oncol."},{"issue":"12","key":"1094_CR176","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1016\/j.ejca.2013.04.002","volume":"49","author":"P Rougier","year":"2013","unstructured":"Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer. 2013;49(12):2633\u201342.","journal-title":"Eur J Cancer."},{"issue":"4","key":"1094_CR177","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jsps.2011.12.001","volume":"20","author":"LD Sasich","year":"2012","unstructured":"Sasich LD, Sukkari SR. The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). Saudi Pharmaceutical J. 2012;20(4):381\u20135.","journal-title":"Saudi Pharmaceutical J."},{"key":"1094_CR178","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0959-8049(01)00230-1","volume":"37","author":"Y Yarden","year":"2001","unstructured":"Yarden Y. The EGFR family and its ligands in human cancer. Eur J Cancer. 2001;37:3\u20138.","journal-title":"Eur J Cancer."},{"issue":"45","key":"1094_CR179","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","volume":"26","author":"MM Moasser","year":"2007","unstructured":"Moasser MM. The oncogene HER2; its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469\u201387.","journal-title":"Oncogene."},{"key":"1094_CR180","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fonc.2012.00062","volume":"2","author":"T Vu","year":"2012","unstructured":"Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast Cancer. Front Oncol. 2012;2:62.","journal-title":"Front Oncol."},{"issue":"4905","key":"1094_CR181","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707.","journal-title":"Science."},{"issue":"11","key":"1094_CR182","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast Cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392.","journal-title":"N Engl J Med."},{"issue":"1","key":"1094_CR183","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab \u2014 mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39\u201351.","journal-title":"N Engl J Med."},{"issue":"11","key":"1094_CR184","first-page":"2661","volume":"6","author":"S Zazo","year":"2016","unstructured":"Zazo S, Gonz\u00e1lez-Alonso P, Mart\u00edn-Aparicio E, Chamizo C, Crist\u00f3bal I, Arp\u00ed O, et al. Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines. Am J Cancer Res. 2016;6(11):2661\u201378.","journal-title":"Am J Cancer Res."},{"issue":"10","key":"1094_CR185","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","volume":"89","author":"P Carter","year":"1992","unstructured":"Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci. 1992;89(10):4285.","journal-title":"Proc Natl Acad Sci."},{"issue":"2","key":"1094_CR186","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","volume":"94","author":"L Arnould","year":"2006","unstructured":"Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94(2):259\u201367.","journal-title":"Br J Cancer."},{"key":"1094_CR187","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443.","journal-title":"Nat Med."},{"issue":"5","key":"1094_CR188","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","volume":"15","author":"TT Junttila","year":"2009","unstructured":"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-independent HER2\/HER3\/PI3K complex is disrupted by Trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15(5):429\u201340.","journal-title":"Cancer Cell."},{"issue":"suppl_1","key":"1094_CR189","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1093\/annonc\/12.suppl_1.S49","volume":"12","author":"J Baselga","year":"2001","unstructured":"Baselga J. Phase I and II clinical trials of trastuzumab. Ann Oncol. 2001;12(suppl_1):S49\u201355.","journal-title":"Ann Oncol"},{"issue":"3","key":"1094_CR190","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719\u201326.","journal-title":"J Clin Oncol."},{"issue":"1","key":"1094_CR191","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13058-015-0568-1","volume":"17","author":"K Strasser-Weippl","year":"2015","unstructured":"Strasser-Weippl K, Horick N, Smith IE, O\u2019Shaughnessy J, Ejlertsen B, Boyle F, et al. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015;17(1):56.","journal-title":"Breast Cancer Res."},{"key":"1094_CR192","doi-asserted-by":"publisher","first-page":"17015","DOI":"10.1038\/sigtrans.2017.15","volume":"2","author":"H Zhang","year":"2017","unstructured":"Zhang H, Wang Y, Wu Y, Jiang X, Tao Y, Yao Y, et al. Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer. Signal Transduct Target Ther. 2017;2:17015.","journal-title":"Signal Transduct Target Ther."},{"issue":"2","key":"1094_CR193","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","volume":"128","author":"TT Junttila","year":"2011","unstructured":"Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128(2):347\u201356.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"1094_CR194","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/1078-0432.CCR-13-0541","volume":"20","author":"I Krop","year":"2014","unstructured":"Krop I, Winer EP. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Clin Cancer Res. 2014;20(1):15\u201320.","journal-title":"Clin Cancer Res."},{"issue":"15_suppl","key":"1094_CR195","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1200\/JCO.2018.36.15_suppl.581","volume":"36","author":"TA Patel","year":"2018","unstructured":"Patel TA, Ensor J, Creamer S, Rodriguez AA, Niravath PA, Darcourt JG, et al. Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study). J Clin Oncol. 2018;36(15_suppl):581.","journal-title":"J Clin Oncol"},{"issue":"19","key":"1094_CR196","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391.","journal-title":"N Engl J Med."},{"issue":"3","key":"1094_CR197","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/CJI.0000000000000115","volume":"39","author":"RL Dillon","year":"2016","unstructured":"Dillon RL, Chooniedass S, Premsukh A, Adams GP, Entwistle J, MacDonald GC, et al. Trastuzumab-deBouganin conjugate overcomes multiple mechanisms of T-DM1 drug resistance. J Immunother. 2016;39(3):117\u201326.","journal-title":"J Immunother."},{"issue":"2","key":"1094_CR198","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/annonc\/mds328","volume":"24","author":"M Capelan","year":"2013","unstructured":"Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273\u201382.","journal-title":"Ann Oncol."},{"issue":"24","key":"1094_CR199","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","volume":"69","author":"W Scheuer","year":"2009","unstructured":"Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of Trastuzumab and Pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330\u20136.","journal-title":"Cancer Res."},{"issue":"2","key":"1094_CR200","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109\u201319.","journal-title":"N Engl J Med."},{"issue":"26","key":"1094_CR201","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733\u201343.","journal-title":"N Engl J Med."},{"issue":"10","key":"1094_CR202","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ctrv.2015.08.001","volume":"41","author":"V D\u2019Amato","year":"2015","unstructured":"D\u2019Amato V, Raimondo L, Formisano L, Giuliano M, De Placido S, Rosa R, et al. Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treat Rev. 2015;41(10):877\u201383.","journal-title":"Cancer Treat Rev."},{"issue":"8","key":"1094_CR203","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.clinthera.2008.08.008","volume":"30","author":"PJ Medina","year":"2008","unstructured":"Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008;30(8):1426\u201347.","journal-title":"Clin Ther."},{"issue":"3","key":"1094_CR204","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","volume":"112","author":"D Cameron","year":"2008","unstructured":"Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533\u201343.","journal-title":"Breast Cancer Res Treat."},{"issue":"Suppl 3","key":"1094_CR205","doi-asserted-by":"publisher","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","volume":"27","author":"B Hallberg","year":"2016","unstructured":"Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol. 2016;27(Suppl 3):iii4\u2013iii15.","journal-title":"Ann Oncol"},{"issue":"10","key":"1094_CR206","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrc3580","volume":"13","author":"B Hallberg","year":"2013","unstructured":"Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer. 2013;13(10):685\u2013700.","journal-title":"Nat Rev Cancer."},{"key":"1094_CR207","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/CLEP.S69718","volume":"6","author":"PL Chia","year":"2014","unstructured":"Chia PL, Mitchell P, Dobrovic A, John T. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol. 2014;6:423\u201332.","journal-title":"Clin Epidemiol."},{"issue":"7153","key":"1094_CR208","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561\u20136.","journal-title":"Nature."},{"issue":"26","key":"1094_CR209","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","volume":"27","author":"AT Shaw","year":"2009","unstructured":"Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247\u201353.","journal-title":"J Clin Oncol."},{"issue":"12","key":"1094_CR210","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/cancers9110148","volume":"9","author":"Abdulraheem Alshareef","year":"2017","unstructured":"Alshareef A. Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers. Cancers. 2017;9(11) https:\/\/doi.org\/10.3390\/cancers9110148 .","journal-title":"Cancers"},{"issue":"2","key":"1094_CR211","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.canlet.2014.05.020","volume":"351","author":"T Kodama","year":"2014","unstructured":"Kodama T, Tsukaguchi T, Yoshida M, Kondoh O, Sakamoto H. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett. 2014;351(2):215\u201321.","journal-title":"Cancer Lett."},{"issue":"18","key":"1094_CR212","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1021\/jm2007613","volume":"54","author":"JJ Cui","year":"2011","unstructured":"Cui JJ, Tran-Dube M, Shen H, Nambu M, Kung PP, Pairish M, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011;54(18):6342\u201363.","journal-title":"J Med Chem."},{"issue":"6","key":"1094_CR213","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","volume":"4","author":"L Friboulet","year":"2014","unstructured":"Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662\u201373.","journal-title":"Cancer Discov."},{"issue":"22","key":"1094_CR214","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","volume":"22","author":"S Zhang","year":"2016","unstructured":"Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, et al. The potent ALK inhibitor Brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin Cancer Res. 2016;22(22):5527\u201338.","journal-title":"Clin Cancer Res."},{"issue":"10","key":"1094_CR215","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","volume":"13","author":"DR Camidge","year":"2012","unstructured":"Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011\u20139.","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"1094_CR216","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1200\/jco.2012.30.15_suppl.7533","volume":"30","author":"D-W Kim","year":"2012","unstructured":"Kim D-W, Ahn M-J, Shi Y, Pas TMD, Yang P-C, Riely GJ, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30(15_suppl):7533.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1094_CR217","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385\u201394.","journal-title":"N Engl J Med."},{"issue":"23","key":"1094_CR218","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167\u201377.","journal-title":"N Engl J Med."},{"key":"1094_CR219","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-016-0251-8","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Savooji J, Liu D. Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol. 2016;9:19.","journal-title":"J Hematol Oncol."},{"issue":"26","key":"1094_CR220","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1056\/NEJMc1404894","volume":"370","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(26):2537\u20139.","journal-title":"N Engl J Med."},{"issue":"17","key":"1094_CR221","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","volume":"33","author":"DB Costa","year":"2015","unstructured":"Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, et al. Clinical experience with Crizotinib in patients with advanced ALK-rearranged non-small-cell lung Cancer and brain metastases. J Clin Oncol. 2015;33(17):1881\u20138.","journal-title":"J Clin Oncol."},{"issue":"23","key":"1094_CR222","doi-asserted-by":"publisher","first-page":"7394","DOI":"10.1158\/1078-0432.CCR-11-1648","volume":"17","author":"JM Heuckmann","year":"2011","unstructured":"Heuckmann JM, Holzel M, Sos ML, Heynck S, Balke-Want H, Koker M, et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res. 2011;17(23):7394\u2013401.","journal-title":"Clin Cancer Res."},{"issue":"6","key":"1094_CR223","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1159\/000430852","volume":"38","author":"G Toyokawa","year":"2015","unstructured":"Toyokawa G, Seto T. Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data. Oncol Res Treat. 2015;38(6):291\u20138.","journal-title":"Oncol Res Treat."},{"issue":"18","key":"1094_CR224","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","volume":"363","author":"YL Choi","year":"2010","unstructured":"Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363(18):1734\u20139.","journal-title":"N Engl J Med."},{"issue":"10072","key":"1094_CR225","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"JC Soria","year":"2017","unstructured":"Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917\u201329.","journal-title":"Lancet."},{"issue":"4","key":"1094_CR226","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","volume":"17","author":"DW Kim","year":"2016","unstructured":"Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452\u201363.","journal-title":"Lancet Oncol."},{"issue":"24","key":"1094_CR227","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2015.65.5936","volume":"34","author":"L Crin\u00f2","year":"2016","unstructured":"Crin\u00f2 L, Ahn M-J, De Marinis F, Groen HJM, Wakelee H, Hida T, et al. Multicenter Phase II study of whole-body and intracranial activity with Ceritinib in patients with ALK-rearranged non\u2013small-cell lung Cancer previously treated with chemotherapy and Crizotinib: results from ASCEND-2. J Clin Oncol. 2016;34(24):2866\u201373.","journal-title":"J Clin Oncol."},{"issue":"15_suppl","key":"1094_CR228","doi-asserted-by":"crossref","first-page":"8060","DOI":"10.1200\/jco.2015.33.15_suppl.8060","volume":"33","author":"E Felip","year":"2015","unstructured":"Felip E, Orlov S, Park K, Yu C-J, Tsai C-M, Nishio M, et al. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-na\u00efve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(15_suppl):8060.","journal-title":"J Clin Oncol"},{"issue":"10072","key":"1094_CR229","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"J-C Soria","year":"2017","unstructured":"Soria J-C, Tan DSW, Chiari R, Wu Y-L, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced <em>ALK<\/em>\u2212rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917\u201329.","journal-title":"Lancet."},{"issue":"7","key":"1094_CR230","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Kim TM, Crino L, Gridelli C, Kiura K, Liu G, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874\u201386.","journal-title":"Lancet Oncol."},{"issue":"9","key":"1094_CR231","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jtho.2017.07.005","volume":"12","author":"BC Cho","year":"2017","unstructured":"Cho BC, Kim DW, Bearz A, Laurie SA, McKeage M, Borra G, et al. ASCEND-8: a randomized Phase 1 study of Ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung Cancer (NSCLC). J Thorac Oncol. 2017;12(9):1357\u201367.","journal-title":"J Thorac Oncol."},{"issue":"5","key":"1094_CR232","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","volume":"19","author":"H Sakamoto","year":"2011","unstructured":"Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011;19(5):679\u201390.","journal-title":"Cancer Cell."},{"issue":"7","key":"1094_CR233","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/S1470-2045(13)70142-6","volume":"14","author":"T Seto","year":"2013","unstructured":"Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013;14(7):590\u20138.","journal-title":"Lancet Oncol."},{"issue":"10","key":"1094_CR234","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","volume":"15","author":"SM Gadgeel","year":"2014","unstructured":"Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study. Lancet Oncol. 2014;15(10):1119\u201328.","journal-title":"Lancet Oncol."},{"issue":"9","key":"1094_CR235","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung Cancer. N Engl J Med. 2017;377(9):829\u201338.","journal-title":"N Engl J Med."},{"issue":"12","key":"1094_CR236","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590\u20139.","journal-title":"Lancet Oncol."},{"issue":"5994","key":"1094_CR237","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/312558a0","volume":"312","author":"K Moelling","year":"1984","unstructured":"Moelling K, Heimann B, Beimling P, Rapp UR, Sander T. Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins. Nature. 1984;312(5994):558\u201361.","journal-title":"Nature."},{"issue":"3","key":"1094_CR238","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.yexmp.2013.10.005","volume":"95","author":"MA Rahman","year":"2013","unstructured":"Rahman MA, Salajegheh A, Smith RA, Lam AK. B-Raf mutation: a key player in molecular biology of cancer. Exp Mol Pathol. 2013;95(3):336\u201342.","journal-title":"Exp Mol Pathol."},{"issue":"11","key":"1094_CR239","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s00018-006-6005-y","volume":"63","author":"A Zebisch","year":"2006","unstructured":"Zebisch A, Troppmair J. Back to the roots: the remarkable RAF oncogene story. Cell Mol Life Sci. 2006;63(11):1314\u201330.","journal-title":"Cell Mol Life Sci."},{"issue":"8","key":"1094_CR240","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.bbamcr.2006.11.010","volume":"1773","author":"JC Chambard","year":"2007","unstructured":"Chambard JC, Lefloch R, Pouyssegur J, Lenormand P. ERK implication in cell cycle regulation. Biochim Biophys Acta. 2007;1773(8):1299\u2013310.","journal-title":"Biochim Biophys Acta."},{"issue":"7","key":"1094_CR241","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3760","volume":"14","author":"M Holderfield","year":"2014","unstructured":"Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14(7):455\u201367.","journal-title":"Nat Rev Cancer."},{"issue":"6892","key":"1094_CR242","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949\u201354.","journal-title":"Nature."},{"key":"1094_CR243","first-page":"21","volume":"7","author":"R Kainthla","year":"2014","unstructured":"Kainthla R, Kim KB, Falchook GS. Dabrafenib for treatment of BRAF-mutant melanoma. Pharmgenomic Pers Med. 2014;7:21\u20139.","journal-title":"Pharmgenomic Pers Med."},{"issue":"9","key":"1094_CR244","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-12-0383","volume":"19","author":"AL Pritchard","year":"2013","unstructured":"Pritchard AL, Hayward NK. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. Clin Cancer Res. 2013;19(9):2301\u20139.","journal-title":"Clin Cancer Res."},{"issue":"4","key":"1094_CR245","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/PAT.0b013e328360b61d","volume":"45","author":"S Pakneshan","year":"2013","unstructured":"Pakneshan S, Salajegheh A, Smith RA, Lam AK. Clinicopathological relevance of BRAF mutations in human cancer. Pathology. 2013;45(4):346\u201356.","journal-title":"Pathology."},{"issue":"6","key":"1094_CR246","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"PT Wan","year":"2004","unstructured":"Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855\u201367.","journal-title":"Cell."},{"issue":"3","key":"1094_CR247","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/00313020801911512","volume":"40","author":"YH Tan","year":"2008","unstructured":"Tan YH, Liu Y, Eu KW, Ang PW, Li WQ, Salto-Tellez M, et al. Detection of BRAF V600E mutation by pyrosequencing. Pathology. 2008;40(3):295\u20138.","journal-title":"Pathology."},{"issue":"23","key":"1094_CR248","first-page":"8132","volume":"63","author":"T Ikenoue","year":"2003","unstructured":"Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res. 2003;63(23):8132\u20137.","journal-title":"Cancer Res."},{"issue":"3","key":"1094_CR249","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","volume":"399","author":"R Roskoski Jr","year":"2010","unstructured":"Roskoski R Jr. RAF protein-serine\/threonine kinases: structure and regulation. Biochem Biophys Res Commun. 2010;399(3):313\u20137.","journal-title":"Biochem Biophys Res Commun."},{"issue":"11","key":"1094_CR250","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nrm1498","volume":"5","author":"C Wellbrock","year":"2004","unstructured":"Wellbrock C, Karasarides M, Marais R. The RAF proteins take Centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875\u201385.","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"12","key":"1094_CR251","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","volume":"18","author":"AM Menzies","year":"2012","unstructured":"Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res. 2012;18(12):3242\u20139.","journal-title":"Clin Cancer Res."},{"issue":"3","key":"1094_CR252","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/1319-3767.207712","volume":"23","author":"Y Li","year":"2017","unstructured":"Li Y, Li W. BRAF mutation is associated with poor clinicopathological outcomes in colorectal cancer: a meta-analysis. Saudi J Gastroenterol. 2017;23(3):144\u20139.","journal-title":"Saudi J Gastroenterol."},{"issue":"3","key":"1094_CR253","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.critrevonc.2013.12.008","volume":"90","author":"MA Rahman","year":"2014","unstructured":"Rahman MA, Salajegheh A, Smith RA, Lam AK. BRAF inhibitors: from the laboratory to clinical trials. Crit Rev Oncol Hematol. 2014;90(3):220\u201332.","journal-title":"Crit Rev Oncol Hematol."},{"issue":"8 Supplement","key":"1094_CR254","first-page":"213","volume":"66","author":"JB Levy","year":"2006","unstructured":"Levy JB, Pauloski N, Braun D, Derome M, Jordan J, Shi H, et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Cancer Res. 2006;66(8 Supplement):213\u20134.","journal-title":"Cancer Res."},{"issue":"5","key":"1094_CR255","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/jnci\/djj069","volume":"98","author":"F Carlomagno","year":"2006","unstructured":"Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98(5):326\u201334.","journal-title":"J Natl Cancer Inst."},{"key":"1094_CR256","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s12885-016-2463-2","volume":"16","author":"A Casadei Gardini","year":"2016","unstructured":"Casadei Gardini A, Chiadini E, Faloppi L, Marisi G, Delmonte A, Scartozzi M, et al. Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC Cancer. 2016;16:429.","journal-title":"BMC Cancer."},{"issue":"5","key":"1094_CR257","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/sj.bjc.6603291","volume":"95","author":"T Eisen","year":"2006","unstructured":"Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95(5):581\u20136.","journal-title":"Br J Cancer."},{"issue":"26","key":"1094_CR258","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293\u2013300.","journal-title":"J Clin Oncol."},{"issue":"3","key":"1094_CR259","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/bjc.2012.287","volume":"107","author":"N P\u00e9cuchet","year":"2012","unstructured":"P\u00e9cuchet N, Lebbe C, Mir O, Billemont B, Blanchet B, Franck N, et al. Sorafenib in advanced melanoma: a critical role for pharmacokinetics? Br J Cancer. 2012;107(3):455\u201361.","journal-title":"Br J Cancer."},{"key":"1094_CR260","doi-asserted-by":"publisher","first-page":"11","DOI":"10.12703\/P5-11","volume":"5","author":"V Morris","year":"2013","unstructured":"Morris V, Kopetz S. BRAF inhibitors in clinical oncology. F1000Prime Rep. 2013;5:11.","journal-title":"F1000Prime Rep."},{"issue":"7315","key":"1094_CR261","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596\u20139.","journal-title":"Nature."},{"issue":"2","key":"1094_CR262","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.bmcl.2011.11.060","volume":"22","author":"A Zambon","year":"2012","unstructured":"Zambon A, Niculescu-Duvaz I, Niculescu-Duvaz D, Marais R, Springer CJ. Small molecule inhibitors of BRAF in clinical trials. Bioorg Med Chem Lett. 2012;22(2):789\u201392.","journal-title":"Bioorg Med Chem Lett."},{"issue":"13","key":"1094_CR263","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.1158\/0008-5472.CAN-10-0646","volume":"70","author":"H Yang","year":"2010","unstructured":"Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 2010;70(13):5518\u201327.","journal-title":"Cancer Res."},{"issue":"12 Supplement","key":"1094_CR264","doi-asserted-by":"publisher","first-page":"B88","DOI":"10.1158\/1535-7163.TARG-09-B88","volume":"8","author":"S Laquerre","year":"2009","unstructured":"Laquerre S, Arnone M, Moss K, Yang J, Fisher K, Kane-Carson LS, et al. Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-Raf<sup>V600E<\/sup> mutation. Mol Cancer Ther. 2009;8(12 Supplement):B88\u2013B.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"1094_CR265","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1517\/17425255.2013.794220","volume":"9","author":"GT Gibney","year":"2013","unstructured":"Gibney GT, Zager JS. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin Drug Metab Toxicol. 2013;9(7):893\u20139.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"1094_CR266","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2407-13-17","volume":"13","author":"G Gentilcore","year":"2013","unstructured":"Gentilcore G, Madonna G, Mozzillo N, Ribas A, Cossu A, Palmieri G, et al. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D\/R) mutations. BMC Cancer. 2013;13:17.","journal-title":"BMC Cancer."},{"issue":"1","key":"1094_CR267","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2017","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid Cancer. J Clin Oncol. 2017;36(1):7\u201313.","journal-title":"J Clin Oncol."},{"issue":"1","key":"1094_CR268","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245\u201355.","journal-title":"Int J Cancer."},{"key":"1094_CR269","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212533","volume":"7","author":"N Personeni","year":"2018","unstructured":"Personeni N, Pressiani T, Santoro A, Rimassa L. Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. Drugs Context. 2018;7:212533.","journal-title":"Drugs Context."},{"issue":"5","key":"1094_CR270","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1177\/1756283X15580743","volume":"8","author":"SK Krishnamoorthy","year":"2015","unstructured":"Krishnamoorthy SK, Relias V, Sebastian S, Jayaraman V, Saif MW. Management of regorafenib-related toxicities: a review. Ther Adv Gastroenterol. 2015;8(5):285\u201397.","journal-title":"Ther Adv Gastroenterol."},{"key":"1094_CR271","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1756-8722-6-30","volume":"6","author":"T Huang","year":"2013","unstructured":"Huang T, Karsy M, Zhuge J, Zhong M, Liu D. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6:30.","journal-title":"J Hematol Oncol."},{"issue":"1","key":"1094_CR272","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1158\/1078-0432.CCR-11-0997","volume":"18","author":"AM Alcala","year":"2012","unstructured":"Alcala AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res. 2012;18(1):33\u20139.","journal-title":"Clin Cancer Res."},{"issue":"14","key":"1094_CR273","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1200\/JCO.2012.44.7888","volume":"31","author":"K Trunzer","year":"2013","unstructured":"Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013;31(14):1767\u201374.","journal-title":"J Clin Oncol."},{"issue":"4","key":"1094_CR274","doi-asserted-by":"publisher","first-page":"336","DOI":"10.18632\/oncotarget.262","volume":"2","author":"RB Corcoran","year":"2011","unstructured":"Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget. 2011;2(4):336\u201346.","journal-title":"Oncotarget."},{"key":"1094_CR275","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","volume":"27","author":"JE Smith-Garvin","year":"2009","unstructured":"Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591\u2013619.","journal-title":"Annu Rev Immunol."},{"issue":"4","key":"1094_CR276","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer."},{"issue":"21","key":"1094_CR277","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543\u201353.","journal-title":"Mol Cell Biol."},{"issue":"5","key":"1094_CR278","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity."},{"issue":"1","key":"1094_CR279","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","volume":"10","author":"SD Blackburn","year":"2009","unstructured":"Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29\u201337.","journal-title":"Nat Immunol."},{"key":"1094_CR280","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in Cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.","journal-title":"Front Oncol."},{"issue":"8","key":"1094_CR281","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","volume":"22","author":"HM Zarour","year":"2016","unstructured":"Zarour HM. Reversing T-cell dysfunction and exhaustion in Cancer. Clin Cancer Res. 2016;22(8):1856\u201364.","journal-title":"Clin Cancer Res."},{"issue":"7109","key":"1094_CR282","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","volume":"443","author":"CL Day","year":"2006","unstructured":"Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7109):350\u20134.","journal-title":"Nature."},{"issue":"6","key":"1094_CR283","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1172\/JCI46102","volume":"121","author":"L Baitsch","year":"2011","unstructured":"Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest. 2011;121(6):2350\u201360.","journal-title":"J Clin Invest."},{"issue":"5256","key":"1094_CR284","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734\u20136.","journal-title":"Science."},{"issue":"3","key":"1094_CR285","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","volume":"65","author":"F Hirano","year":"2005","unstructured":"Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089\u201396.","journal-title":"Cancer Res."},{"key":"1094_CR286","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","volume":"23","author":"RJ Greenwald","year":"2005","unstructured":"Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515\u201348.","journal-title":"Annu Rev Immunol."},{"issue":"1","key":"1094_CR287","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/gene.2013.57","volume":"15","author":"DV Chan","year":"2014","unstructured":"Chan DV, Gibson HM, Aufiero BM, Wilson AJ, Hafner MS, Mi QS, et al. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes Immun. 2014;15(1):25\u201332.","journal-title":"Genes Immun."},{"issue":"8","key":"1094_CR288","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1073\/pnas.0830997100","volume":"100","author":"FS Hodi","year":"2003","unstructured":"Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100(8):4712\u20137.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"7","key":"1094_CR289","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1634\/theoncologist.12-7-873","volume":"12","author":"A Ribas","year":"2007","unstructured":"Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, Bernstein SH, et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist. 2007;12(7):873\u201383.","journal-title":"Oncologist."},{"issue":"2","key":"1094_CR290","doi-asserted-by":"publisher","first-page":"171","DOI":"10.20892\/j.issn.2095-3941.2016.0015","volume":"13","author":"SJ Harris","year":"2016","unstructured":"Harris SJ, Brown J, Lopez J, Yap TA. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med. 2016;13(2):171\u201393.","journal-title":"Cancer Biol Med."},{"issue":"2","key":"1094_CR291","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2165\/11584530-000000000-00000","volume":"10","author":"Tremelimumab","year":"2010","unstructured":"Tremelimumab. Drugs RD. 2010;10(2):123\u201332.","journal-title":"Drugs RD."},{"issue":"19","key":"1094_CR292","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1158\/1078-0432.CCR-16-0249","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens A, Wistuba-Hamprecht K, Yuan J, Postow MA, Wong P, Capone M, et al. Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with Ipilimumab. Clin Cancer Res. 2016;22(19):4848\u201358.","journal-title":"Clin Cancer Res."},{"issue":"8","key":"1094_CR293","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med."},{"issue":"2","key":"1094_CR294","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.coi.2006.01.011","volume":"18","author":"KS Peggs","year":"2006","unstructured":"Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18(2):206\u201313.","journal-title":"Curr Opin Immunol."},{"issue":"12","key":"1094_CR295","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365\u20139.","journal-title":"Nat Med."},{"issue":"7","key":"1094_CR296","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334.","journal-title":"J Exp Med."},{"key":"1094_CR297","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jmgm.2015.01.015","volume":"57","author":"C Viricel","year":"2015","unstructured":"Viricel C, Ahmed M, Barakat K. Human PD-1 binds differently to its human ligands: a comprehensive modeling study. J Mol Graph Modell. 2015;57:131\u201342.","journal-title":"J Mol Graph Modell."},{"issue":"19","key":"1094_CR298","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293\u20137.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"8","key":"1094_CR299","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793\u2013800.","journal-title":"Nat Med."},{"key":"1094_CR300","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2016.29","volume":"1","author":"S Tan","year":"2016","unstructured":"Tan S, Zhang CW, Gao GF. Seeing is believing: anti-PD-1\/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. Signal Transduct Target Ther. 2016;1:16029.","journal-title":"Signal Transduct Target Ther."},{"issue":"21","key":"1094_CR301","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328.","journal-title":"N Engl J Med."},{"issue":"9948","key":"1094_CR302","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109\u201317.","journal-title":"Lancet."},{"issue":"19","key":"1094_CR303","doi-asserted-by":"publisher","first-page":"5666","DOI":"10.1158\/1078-0432.CCR-16-0663","volume":"23","author":"MK Chuk","year":"2017","unstructured":"Chuk MK, Chang JT, Theoret MR, Sampene E, He K, Weis SL, et al. FDA approval summary: accelerated approval of Pembrolizumab for second-line treatment of metastatic melanoma. Clin Cancer Res. 2017;23(19):5666\u201370.","journal-title":"Clin Cancer Res."},{"issue":"11","key":"1094_CR304","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483\u201392.","journal-title":"Lancet Oncol."},{"issue":"5","key":"1094_CR305","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623\u201330.","journal-title":"Lancet Oncol."},{"issue":"6349","key":"1094_CR306","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313.","journal-title":"Science."},{"issue":"5","key":"1094_CR307","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of Pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction Cancer: Phase 2 clinical KEYNOTE-059 trial. JAMA Oncology. 2018;4(5):e180013.","journal-title":"JAMA Oncology."},{"issue":"32","key":"1094_CR308","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","volume":"34","author":"LQM Chow","year":"2016","unstructured":"Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumor activity of Pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the Phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34(32):3838\u201345.","journal-title":"J Clin Oncol."},{"issue":"22","key":"1094_CR309","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med."},{"issue":"19","key":"1094_CR310","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167\u201375.","journal-title":"J Clin Oncol."},{"issue":"3","key":"1094_CR311","doi-asserted-by":"publisher","first-page":"410","DOI":"10.7150\/jca.17144","volume":"8","author":"L Guo","year":"2017","unstructured":"Guo L, Zhang H, Chen B. Nivolumab as programmed Death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer. 2017;8(3):410\u20136.","journal-title":"J Cancer."},{"issue":"4","key":"1094_CR312","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375\u201384.","journal-title":"Lancet Oncol."},{"issue":"14","key":"1094_CR313","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-16-0712","volume":"23","author":"M Hazarika","year":"2017","unstructured":"Hazarika M, Chuk MK, Theoret MR, Mushti S, He K, Weis SL, et al. U.S. FDA approval summary: Nivolumab for treatment of Unresectable or metastatic melanoma following progression on Ipilimumab. Clin Cancer Res. 2017;23(14):3484\u20138.","journal-title":"Clin Cancer Res."},{"issue":"11","key":"1094_CR314","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1231292","volume":"5","author":"O Hasan Ali","year":"2016","unstructured":"Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, et al. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology. 2016;5(11):e1231292.","journal-title":"Oncoimmunology."},{"issue":"1","key":"1094_CR315","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13054-017-1678-1","volume":"21","author":"F Kroschinsky","year":"2017","unstructured":"Kroschinsky F, St\u00f6lzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21(1):89.","journal-title":"Crit Care."},{"issue":"17","key":"1094_CR316","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med."},{"issue":"9","key":"1094_CR317","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182\u201391.","journal-title":"Lancet Oncol."},{"issue":"4","key":"1094_CR318","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311\u20139.","journal-title":"N Engl J Med."},{"issue":"9","key":"1094_CR319","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283\u201394.","journal-title":"Lancet Oncol."},{"issue":"10088","key":"1094_CR320","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet."},{"issue":"11","key":"1094_CR321","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","volume":"17","author":"P Sharma","year":"2016","unstructured":"Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial. Lancet Oncol. 2016;17(11):1590\u20138.","journal-title":"Lancet Oncol."},{"issue":"13","key":"1094_CR322","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMc1509660","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270\u20131.","journal-title":"N Engl J Med."},{"issue":"11","key":"1094_CR323","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167251","volume":"11","author":"MJ Selby","year":"2016","unstructured":"Selby MJ, Engelhardt JJ, Johnston RJ, Lu LS, Han M, Thudium K, et al. Correction: preclinical development of Ipilimumab and Nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and Cynomolgus macaque toxicology. PLoS One. 2016;11(11):e0167251.","journal-title":"PLoS One."},{"issue":"4","key":"1094_CR324","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1358\/dot.2017.53.4.2589163","volume":"53","author":"A Krishnamurthy","year":"2017","unstructured":"Krishnamurthy A, Jimeno A. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers. Drugs Today. 2017;53(4):217\u201337.","journal-title":"Drugs Today."},{"issue":"10031","key":"1094_CR325","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet."},{"key":"1094_CR326","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fonc.2018.00277","volume":"8","author":"R Ryu","year":"2018","unstructured":"Ryu R, Ward KE. Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects. Front Oncol. 2018;8:277.","journal-title":"Front Oncol."},{"issue":"10031","key":"1094_CR327","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet."},{"issue":"6","key":"1094_CR328","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1634\/theoncologist.2017-0087","volume":"22","author":"Y-M Ning","year":"2017","unstructured":"Ning Y-M, Suzman D, Maher VE, Zhang L, Tang S, Ricks T, et al. FDA approval summary: Atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy. Oncologist. 2017;22(6):743\u20139.","journal-title":"Oncologist."},{"issue":"12","key":"1094_CR329","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40265-017-0782-5","volume":"77","author":"YY Syed","year":"2017","unstructured":"Syed YY. Durvalumab: first global approval. Drugs. 2017;77(12):1369\u201376.","journal-title":"Drugs."},{"issue":"15_suppl","key":"1094_CR330","doi-asserted-by":"publisher","first-page":"TPS4574","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS4574","volume":"34","author":"T Powles","year":"2016","unstructured":"Powles T, Galsky MD, Castellano D, Van Der Heijden MS, Petrylak DP, Armstrong J, et al. A phase 3 study of first-line durvalumab (MEDI4736) \u00b1 tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE. J Clin Oncol. 2016;34(15_suppl):TPS4574.","journal-title":"J Clin Oncol."},{"issue":"20","key":"1094_CR331","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in stage III non-small-cell lung Cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med."},{"key":"1094_CR332","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.3389\/fimmu.2018.02140","volume":"9","author":"EP Juli\u00e1","year":"2018","unstructured":"Juli\u00e1 EP, Amante A, Pampena MB, Mordoh J, Levy EM. Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. Front Immunol. 2018;9:2140.","journal-title":"Front Immunol."},{"issue":"10","key":"1094_CR333","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385.","journal-title":"Lancet Oncol."},{"issue":"19","key":"1094_CR334","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","volume":"35","author":"AB Apolo","year":"2017","unstructured":"Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, et al. Avelumab, an anti\u2013programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, Phase Ib study. J Clin Oncol. 2017;35(19):2117\u201324.","journal-title":"J Clin Oncol."},{"issue":"1","key":"1094_CR335","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"MR Patel","year":"2018","unstructured":"Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. 2018;19(1):51\u201364.","journal-title":"Lancet Oncol."},{"key":"1094_CR336","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","volume":"13","author":"A Bertrand","year":"2015","unstructured":"Bertrand A, Kostine M, Barnetche T, Truchetet M-E, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.","journal-title":"BMC Med."},{"issue":"1","key":"1094_CR337","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","volume":"6","author":"AJ Giles","year":"2018","unstructured":"Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018;6(1):51.","journal-title":"J Immunother Cancer."},{"issue":"3","key":"1094_CR338","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/phar.1714","volume":"36","author":"PJ Medina","year":"2016","unstructured":"Medina PJ, Adams VR. PD-1 pathway inhibitors: Immuno-oncology agents for restoring antitumor immune responses. Pharmacotherapy. 2016;36(3):317\u201334.","journal-title":"Pharmacotherapy."},{"issue":"19","key":"1094_CR339","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","volume":"36","author":"GC Leonardi","year":"2018","unstructured":"Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, et al. Safety of programmed Death-1 pathway inhibitors among patients with non-small-cell lung Cancer and preexisting autoimmune disorders. J Clin Oncol. 2018;36(19):1905\u201312.","journal-title":"J Clin Oncol."},{"issue":"1","key":"1094_CR340","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-018-0349-3","volume":"6","author":"YK Chae","year":"2018","unstructured":"Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, et al. Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):39.","journal-title":"J Immunother Cancer."},{"key":"1094_CR341","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2017.00202","volume":"7","author":"SR Jhawar","year":"2017","unstructured":"Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, Kohlhapp FJ, Goyal S, et al. Oncolytic viruses\u2014natural and genetically engineered Cancer immunotherapies. Front Oncol. 2017;7:202.","journal-title":"Front Oncol."},{"issue":"8","key":"1094_CR342","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-14-2662","volume":"21","author":"F McCormick","year":"2015","unstructured":"McCormick F. KRAS as a therapeutic target. Clin Cancer Res. 2015;21(8):1797\u2013801.","journal-title":"Clin Cancer Res."}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1094-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1094-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1094-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T16:42:32Z","timestamp":1694796152000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1094-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":342,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1094"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1094-2","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"30 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"156"}}